Background Dendritic cells (DC) mediate inflammation in rodent models of allergic airway disease, but the role played by human respiratory-tract DC (hRTDC) in atopic asthma remains poorly defined. Recent data suggest that CD1 antigen presentation by hRTDC may contribute to asthma pathogenesis. Objective To investigate the influence of hRTDC on the balance between atopy and allergic asthma in human subjects and to determine whether CD1 expression by hRTDC is modulated during asthmatic inflammation. Methods Sputum cells were induced from steroid-naïve, allergen-challenged and allergennaïve subjects (atopic asthmatics, atopic non-asthmatics and non-atopic controls). hRTDC were identified using monoclonal antibody labelling and analysis by flow cytometry. Results hRTDC stained HLA-DR 1 (negative for markers of other cell lineages) were predominantly myeloid and comprised $0.5% of viable sputum cells. Sputum cells were potent stimulators of allogeneic CD4 1 naïve T cells and enrichment/depletion experiments correlated stimulatory potency with DC numbers. Sputum contained cells that exhibited typical dendritic morphology when analysed by electron microscopy. Myeloid hRTDC were endocytically active, but uptake of FITC-dextran was enhanced in cells from asthmatics (P o 0.001). Despite their increased endocytic capacity, asthmatic myeloid hRTDC appeared mature and expressed increased levels of maturation markers (P o 0.05-P o 0.001), CD1c, CD1d and langerin (P o 0.05). CD1c expression by asthmatic myeloid hRTDC was enhanced upon in vivo allergen challenge (three to ninefold within 24 h; P o 0.05). CD11c À CD123 high hRTDC were only detected in asthmatic sputum and were increased in number following allergen challenge. Conclusion Despite limited cell numbers, it proved possible to analyse human RTDC in induced sputum, providing evidence that increased antigen uptake and enhanced CD1 presentation by activated hRTDC may contribute to allergic airway disease. CD1 presentation by hRTDC in atopic asthma may therefore constitute a novel target for future intervention strategies.
Summary
Background Dendritic cells (DC) mediate inflammation in rodent models of allergic airway disease, but the role played by human respiratory-tract DC (hRTDC) in atopic asthma remains poorly defined. Recent data suggest that CD1 antigen presentation by hRTDC may contribute to asthma pathogenesis. Objective To investigate the influence of hRTDC on the balance between atopy and allergic asthma in human subjects and to determine whether CD1 expression by hRTDC is modulated during asthmatic inflammation. Methods Sputum cells were induced from steroid-naïve, allergen-challenged and allergennaïve subjects (atopic asthmatics, atopic non-asthmatics and non-atopic controls). hRTDC were identified using monoclonal antibody labelling and analysis by flow cytometry. Results hRTDC stained HLA-DR 1 (negative for markers of other cell lineages) were predominantly myeloid and comprised $0.5% of viable sputum cells. Sputum cells were potent stimulators of allogeneic CD4 1 naïve T cells and enrichment/depletion experiments correlated stimulatory potency with DC numbers. Sputum contained cells that exhibited typical dendritic morphology when analysed by electron microscopy. Myeloid hRTDC were endocytically active, but uptake of FITC-dextran was enhanced in cells from asthmatics (P o 0.001). Despite their increased endocytic capacity, asthmatic myeloid hRTDC appeared mature and expressed increased levels of maturation markers (P o 0.05-P o 0.001), CD1c, CD1d and langerin (P o 0.05). CD1c expression by asthmatic myeloid hRTDC was enhanced upon in vivo allergen challenge (three to ninefold within 24 h; P o 0.05). CD11c À CD123 high incorporates multiple different isoforms (CD1a, CD1b, CD1c and CD1d) [4 -6] . DC mediate the immune response to inhaled allergens and are thought to play a critical role in asthma pathogenesis [7] , but detailed analyses of respiratory-tract DC (RTDC) are currently limited to studies in animal systems. Recent data suggest that CD1 antigen presentation by human respiratory-tract dendritic cells (hRTDC) may contribute to asthma pathogenesis [8] .
Indeed, in the case of phospholipid antigens extracted from pollen, CD1a and CD1d expressed by monocytederived DC are involved in antigen binding and presentation to a number of different ab and gd T cell subsets, including natural killer T cells (NKT cells) [9] . These observations lead to the hypothesis that hRTDC expression of CD1 molecules is altered in asthma and contributes to disease pathogenesis by stimulating CD1-restricted lymphocytes (such as NKT cells) in the pulmonary tissues [10] . However, it is currently unknown whether CD1 expression by RTDC is modulated in the asthmatic human lung.
In murine models, altering the balance of DC subsets in the lung is sufficient to induce pulmonary eosinophilia [11] , while under non-inflammatory conditions, DC can produce regulatory cytokines and mediate allergen tolerance [12] . However, the extent to which data from mouse models of asthma can be extrapolated to the human disease remains unclear [13] , and a number of key points arising from murine models remain untested in the human system.
DC are known to reside in the asthmatic lung and increase in number following allergen challenge [14] . However, many early studies of hRTDC used isolation protocols that incorporated culture steps that we now recognize induce phenotypic and functional changes in DC [15, 16] . We have developed a non-invasive approach to the analysis of hRTDC in induced sputum that limits ex vivo manipulation, thereby minimizing inadvertent effects upon DC phenotype. Multi-parameter analysis of unmanipulated hRTDC by flow cytometry allows unambiguous identification of DC subsets and quantitative analysis of their phenotype that has not previously been possible using only histological approaches. Indeed, detailed characterization of the predominant DC subset in murine lung has only recently been reported [17] , and comparable data for the human airways are not yet available.
Using a novel, multi-parameter approach, we aimed to investigate the influence of hRTDC on the balance between atopy and allergic asthma in human subjects and to determine whether CD1 expression by hRTDC is modulated during asthmatic inflammation. Here, we report the successful characterization of the trace DC populations present in sputum from human subjects and identify changes in DC activation, antigen uptake and expression of CD1c and CD1d that are specifically associated with atopic asthma. Furthermore, we demonstrate that hRTDC expression of co-stimulatory molecules and CD1c antigen-presenting molecules is modulated upon allergen inhalation. These findings support a critical role for CD1 1 human RTDC in the pathogenesis of allergic asthma.
Methods

Subjects
Sputum donors (non-atopic control = 12, atopic-asthmatic = 15, atopic non-asthmatic = 6) were light/nonsmokers. Smoking was prohibited for X1 year preceding the study, steroids excluded for X1 month prior and antihistamines precluded for X24 h before induction. Volunteers were in good general health and free from respiratory infection for X1 month before taking part. Written, informed consent was obtained from all participants. The study was approved by the Harrow Research Ethics Committee.
Spirometry
Lung function was measured using routine spirometry (Vitalograph, Bucks or Jaeger-Masterscope, Wurzberg, Germany). Asthmatic subjects presented with mild, reversible airway obstruction and a clinical history of asthma (Table 1) .
Skin-prick testing D. pteronyssinus, dog, cat, feathers, grass pollen, C. herbarum, A. alternata, C. albicans, and A. fumigatus (ALK-Abelló, Hrsholm). Atopic donors displayed positive reactions to X2 aeroallergens or exhibited an atopic family history and 1 positive reaction.
Allergen challenge
The allergen challenge procedure was modified from published guidelines [18] . Asthmatic subjects who exhibited a forced expiratory volume in 1 s (FEV 1 ) 4 70% of predicted values, a positive skin test to Der p 1 and/or Fel d 1 and methacholine PC 20 o 8 mg/mL were challenged with the corresponding allergen (Aquagen SQ, 250 -64 000 U/mL; ALK-Abelló). Subjects inhaled five breaths of normal saline (0.9%) from a dosimeter (Mefar, Brescia, Italy) and gave two consistent measurements of FEV 1 at 5 and 10 min post-saline inhalation. Allergen was administered in the same way as the saline with FEV 1 measurements being taken at 5 min intervals. Where FEV 1 fell o 15% from post-saline baseline, the allergen dose was doubled. Where FEV 1 declined 15-20% from post-saline baseline, the allergen dose was unchanged. The challenge procedure continued until a X20% decline in FEV 1 was achieved.
Sputum induction
Sputum induction and processing were consistent with published guidelines [19] . 
Sputum processing
Mucus plugs were weighed and digested in a fourfold quantity of 0.1% v/v dithiothreitol (Calbiochem, San Diego, CA, USA). The digestion mixture was incubated at 37 1C for 20 min and then diluted 1:1 with PBS. The resultant cell suspension was filtered through 48 mm gauze and centrifuged (650 g, 4 1C, 10 min). The supernatant was discarded and the cells were re-suspended in PBS.
Antibody labelling
Sputum cells were labelled with mAb on ice for 20 min; anti-CD1d (clone CD1d42), b7 Integrin (FIB504), CD80 (L307.4), CD83(HB15e), CD123(9F5), CD34(581) and HLA-DR(G46-6) were from BD Biosciences (Cardiff, UK). Anti-CD3(UCHT1), CD14(RMO52), CD16(3G8), CD19(J4.119), CD124(S456C9), langerin(DCGM4) and CD56(N901) were from Beckman Coulter (High Wycombe, UK). Anti-CD1a (NA1/34), CD40(LOB7/6) and CD86(BU63) were from Serotec (Oxford, UK). Anti-CD1c(AD5-8E7) and BDCA-3(AD5-14H12) were from Miltenyi Biotec (Bisley, UK). Anti-DC-SIGN(120507) was from R&D Systems (Abingdon, UK) and anti-CD11c(KB90) was from Dako Cytomation (Ely, UK). Corresponding isotype-matched controls were purchased from the respective manufacturers. Nonspecific binding was blocked by addition of fetal calf serum (FCS) before labelling. The labelled cells were washed in FACS buffer (PBS, 2% FCS, 0.02% sodium azide, 1 mM EDTA) and centrifuged (500 g, 4 1C, 5 min). The supernatants were discarded, and the cell pellets fixed in 1% paraformaldehyde.
Flow cytometry
Data acquisition was by a FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK), and analysis using WinList software (Verity, Maine). Live cells were analysed on a plot of HLA-DR vs. lineage cocktail staining (lin; mAb labels for CD3, CD14, CD16, CD19, CD34 and CD56 against unwanted cell lineages). DC were identified as HLA-DR 1 lin À /dim cells. The proportion of label 1 cells was measured by gating on events that exceeded the fluorescence range of the isotype control. Enhanced normalized subtraction was used to measure the staining intensity of the positive cells (expressed as the positive intensity/PI ratio relative to the isotype control).
Endocytosis assay
Sputum cells in complete medium (Dutch-modified RPMI-1640, 10% FCS, 100 mM/Lu penicillin, 100 mgm ml À 1 streptomycin, 20 mM L-glutamine) were incubated at 4 1C or 37 1C ml 
Mixed leucocyte reaction (MLR)
Human whole blood was diluted 2:1 with Dutch-modified RPMI-1640 before centrifugation over Ficoll-Paque (Amersham Bioscience) at 650 g for 20 min. Peripheral blood mononuclear cells (PBMC) were harvested from the interface and washed in complete medium. CD4 1 naïve T cells were negatively selected from PBMC using StemSep (StemCell Technologies, Vancouver, Canada) and separated on Mini-MACS columns (Miltenyi Biotec). The resultant cells were labelled with 5 mM CFSE (Invitrogen, Paisley, UK) for 3 min at room temperature, and the reaction was stopped by addition of FCS.
Unfractionated sputum cells, and sputum cells enriched for or depleted of DC, were used as stimulator cells in an allogeneic MLR with CFSE-labelled, CD4
1 naïve T cells. Sputum cells were depleted of DC by cell sorting (gated on Enriched blood DC were obtained from the non-adherent fraction of PBMC cultured overnight (37 1C, 5% CO 2 ) in complete medium at $4 Â 10 6 cells/mL. The non-adherent cells were centrifuged over NycoPrep (10 min, 500 g; Axis-shield, Oslo, Norway) and the low-density cells harvested from the interface. Responder cells were plated out in 96-well flat-bottom plates at $400 000 cells per well (cpw). The stimulator cells were added at $8000 cpw. After 5 days of culture, the cells were harvested and analysed by flow cytometry. Proliferating cells were identified by reduction in CFSE staining, and their number was determined by reference to FlowCount beads (Beckman Coulter).
Electron microscopy
Sputum cells were immuno-gold labelled against HLA-DR (L243, BD Biosciences; goat anti-biotin 10 nm gold, BB International), fixed in 3% glutaraldehyde, embedded in low gelling temperature agarose (Sigma-Aldrich, Poole, UK), further fixed in 1% osmium tetroxide and then stained with 2% uranyl acetate. The cells were dehydrated using an acetone gradient, embedded in araldite resin and cured for 18 h at 65 1C. Blocks of cells were cut into $100 nm sections and collected onto copper grids. Sections were stained with Reynold's lead citrate and viewed on a Jeol JEM-1200EX electron microscope (Jeol, Welwyn Garden City, UK).
Statistics
Statistical analyses were performed using SigmaStat software (SPSS, Chicago, IL, USA). Pooled data are expressed as mean values AE standard error. t-tests were used to analyse normally distributed data and Mann-Whitney rank-sum tests were used to analyse non-normally distributed data. Two-way analysis of variance was used to test the endocytosis data. P o 0.05 was considered to be significant.
Results
Identification of hRTDC in sputum
Cells exhibiting a characteristic DC phenotype (HLA-DR 1 lineage À /dim ) were detected in sputum by flow cytometry (Fig. 1a-R1 ). The size and granularity of this population were typical of DC ( Fig. 1b-R2 ; black events). hRTDC stained predominantly CD11c 1 (Fig. 1c-R3 ), and their identity was confirmed by immuno-gold electron microscopy ( Fig. 1d) .
hRTDC comprised $0.5% of viable sputum cells in allergen-naïve subjects and there was a tendency towards elevated proportions of hRTDC in asthmatic sputum cells (%hRTDC in sputum cells; control, 0.31 AE 0.06%; atopic, 0.36 AE 0.08%; asthmatic, 0.64 AE 0.15%). The total number of hRTDC obtained by sputum induction was significantly higher in asthmatic subjects than in healthy control donors ( Fig. 2a; P o 0.05) . However, when these values were corrected for the mass of sputum plugs obtained, this difference between asthmatic and healthy control donors was no longer statistically significant (hRTDC number; 24 AE 6 Â 10 3 g
, n = 12 asthmatic subjects; vs. 42 AE 11 Â10 3 g À 1 , n = 12 healthy control donors; P 4 0.05), suggesting that increased airway secretions in asthma may partially contribute to elevated DC numbers. Putative plasmacytoid/CD11c À DC comprised less than 30% of hRTDC in each of the subject groups analysed (Fig. 2b) , and sputum from atopic subjects contained a significantly lower proportion of these cells than was detected in control subjects (P o 0.05).
hRTDC are potent stimulatory cells
Sputum cells stimulated CD4
1 naïve T cells to proliferate with a potency comparable with that of mature blood DC (Figs 3a and b) . The small number of cells available in sputum prevented DC purification, but partial enrichment/ depletion of hRTDC in sputum cells was used to assay their contribution to the stimulatory effects observed. Sputum cells stimulated significant levels of naïve T cell proliferation (Fig. 3c) . However, partial depletion of myeloid hRTDC from sputum cells by cell sorting resulted in a 43% reduction in the number of dividing cells detected (Fig. 3d) . A similar reduction was achieved by depletion of langerin 1 cells (putative CD11c 1 hRTDC) using column fractionation. In contrast, enriching for this langerin 1 subset increased T cell proliferation $2.5-fold compared with the unseparated sputum cells stimulus (Fig. 3e) .
Enhanced antigen uptake by asthmatic hRTDC
Endocytosis by CD11c
1 hRTDC was rapid and sustained, but asthmatic cells displayed greater activity than their control or atopic counterparts ( Fig. 4 ; P o 0.001). Plasmacytoid DC displayed minimal endocytic activity. In contrast, HLA-DR 1 lin 1 monocyte/macrophages (Mo/MF) displayed $36-fold higher levels of uptake than CD11c 1 hRTDC. While Mo/MF from control donors were the most endocytic of the subject groups (P o 0.001 compared with asthmatic or atopic Mo/MF), hRTDC from these subjects were the least effective at antigen uptake.
Elevated expression of CD1c, CD1d, langerin and maturation markers by CD11c
1 hRTDC in asthma hRTDC were labelled with mAb against various DC subsetting and maturation markers. The proportion of positive cells (%) and the expression level of each marker (positive intensity/PI ratio) were determined relative to isotype-matched controls. Myeloid hRTDC from control subjects expressed only low levels of co-stimulatory molecules. In contrast, hRTDC from asthmatics exhibited a phenotype suggestive of mature DC; they expressed significantly higher levels of CD80 (PI: 11 AE 2) and CD86 (PI: 14 AE 3) than hRTDC from controls (PI: 4 AE 1 for CD80; 5 AE 1 for CD86 - Fig. 5a ). The proportion of hRTDC expressing CD80 or CD86 in asthmatic sputum (50 AE 5% and 71 AE 4%, respectively) was also significantly higher than was detected in sputum from control (CD80, 23 AE 6%; CD86, 38 AE 6%) or atopic subjects (CD80; 24 AE 7%; CD86, 41 AE 10% - Fig. 5b ).
Changes in hRTDC phenotype associated with asthma were not confined to activation markers alone. Asthmatic CD11c 1 hRTDC expressed significantly higher levels of CD1c, CD1d, CD123 and langerin than equivalent cells 25 from control subjects (Fig. 5a ). The proportion of CD11c 1 hRTDC expressing CD1c was also significantly increased (asthmatic, 70 AE 5%; control, 39 AE 7%), and whereas few CD1d 1 cells were detected among the hRTDC population of control or atopic donors (o 2% stained CD1d 1 in these subject groups), there was a significant number of CD1d 1 DC in sputum from asthmatics (11 AE 4% - Fig. 5b ).
CD11c
À 'hRTDC' from asthmatic donors include CD123 high cells and display elevated CD40 expression CD11c À 'hRTDC' stained only weakly with most of the reagents tested. It is therefore unclear whether these cells correspond to conventional CD11c À plasmacytoid DC. Cells expressing high levels of CD123 (a hallmark of plasmacytoid DC in peripheral blood) were only detected in sputum from asthmatic donors, and then only in small numbers. Despite their indeterminate origins, CD40 expression was both increased on these cells and detected on a greater proportion of their population in sputum from asthmatics (Fig. 6) .
In a subset of donors, sputum was obtained on two separate occasions approximately one week apart (n = 3 per allergen-naïve subject group). Surface labelling analyses were performed on both occasions to assess phenotype stability over time. Despite diurnal variability in the disease symptoms of asthmatic subjects, CD11c 1 hRTDC exhibited a remarkably consistent phenotype in each of the subject groups analysed (Fig. 7) .
Allergen challenge enhances CD1c expression by hRTDC
In a subset of asthmatics, sputum was obtained on three separate occasions over the course of an allergen challenge. hRTDC phenotype was analysed pre-challenge, 24 h post and 72 h post-challenge. The pre-challenge and 24 h post-challenge analyses are shown in Fig. 8 .
hRTDC from asthmatic subjects comprised $0.5% of viable sputum cells before allergen administration, but by 24 h post-challenge the proportion of hRTDC had increased between 1.6-and 9.5-fold. The proportion of hRTDC expressing CD11c also increased markedly following allergen inhalation (54 AE 10% in allergen-naïve sputum, 82 AE 4% in post-challenge samples, data not shown).
Expression of CD1c by asthmatic myeloid hRTDC was increased between 3-and 9-fold within 24 h of allergen administration (P o 0.05; Fig. 8 ). In two of three donors, CD1c expression declined to an intermediate level at 72 h post-challenge (between 1.9-and 3.6-fold of allergennaïve baseline) but in the third subject, CD1c expression was increased yet further ($19-fold of allergen-naïve baseline, data not shown). Langerin expression by asthmatic myeloid hRTDC was also augmented following allergen inhalation; 24 h post-challenge, levels of staining had increased to more than double those observed on autologous, allergen-naïve cells. CD40 and CD86 expression by CD11c 1 hRTDC from asthmatic subjects were also enhanced upon allergen challenge -the intensity of staining for these co-stimulatory molecules approximately doubled on pre-challenge levels. In addition, allergen challenge increased the proportion of CD11c
high hRTDC detected in asthmatic sputum (Fig. 8) , although detected no other marked effects upon the CD11c À population were detected.
Discussion
hRTDC were successfully identified in induced sputum using multi-colour flow cytometry. This non-invasive approach revealed that hRTDC activation, increased capacity for antigen uptake and enhanced expression of CD1c and CD1d are specifically associated with atopic asthma. hRTDC displayed a typical DC phenotype, morphology and functional characteristics. Sputum cells stimulated the proliferation of CD4 1 naïve T cells with a potency comparable with that of mature blood DC. Although purification was prohibited by low cell numbers, enrichment/depletion of DC in sputum cells identified hRTDC as the major stimulatory cells present. Consistent with these data, CD1a
1 DC from bronchoalveolar lavage fluid are reported to be potent accessory cells [20] , whereas alveolar macrophages are defective in this role [21] .
hRTDC comprised o 0.4% of viable sputum cells from control or atopic subjects, but $0.6% of viable sputum cells from asthmatic subjects. Small numbers of CD123 high CD11c
À hRTDC were consistently detected, but only in asthmatic sputum. Moreover, allergen inhalation increased the number of CD123 high CD11c
À hRTDC observed in asthmatic sputum, alongside increases in the number of myeloid hRTDC detected -both in direct correlation with airflow obstruction. These data suggest recruitment of circulating DC precursors to the inflamed asthmatic mucosa [14] , and support a role for CD11c 1 RTDC as pro-inflammatory mediators in allergic airway disease [11] . In a murine model of asthma, plasmacytoid DC mediate allergen tolerance in the thoracic lymph nodes by inhibiting the pro-inflammatory effects of myeloid RTDC [22] . However, it is unclear whether the CD123 high
CD11c
À hRTDC described by the current study correspond to the 'tolerogenic' murine population reported by other investigators, or whether these cells are similarly capable of suppressing inflammation in the human lung.
The conventional model of DC maturation associates enhanced stimulatory potency with decreased endocytic capacity [3] . However, despite the increased maturity of myeloid hRTDC in asthma, these cells were more endocytic than their control or atopic counterparts and expressed high levels of langerin, a receptor for antigen internalization [23] . Allergen challenge further increased langerin expression by asthmatic myeloid hRTDC, despite a concomitant increase in the expression of maturation markers. These data indicate that the regulation of stimulatory capacity and antigen acquisition can be uncoupled in the airways. In asthma, this dichotomy of function may permit continuous sampling and presentation of respiratory antigen by mature, stimulatory hRTDC. Indeed, the reduced endocytic activity displayed by sputum Mo/MF in asthma could contribute to this effect by allowing respiratory antigen to accumulate in the airways and increase hRTDC exposure to maturational stimuli.
hRTDC expression of langerin, CD1c and CD1d was significantly increased in asthma. CD1c 1 DC have been described at sites of airway inflammation by other investigators [6, 14] , but our data extend these findings in several ways. Firstly, we have been able to quantify asthma-related changes in the hRTDC phenotype at the single-cell level, revealing that local up-regulation of CD1c expression, as well as enhanced recruitment, can underlie allergen-driven increases in CD1c 1 hRTDC in the asthmatic lung [14] . Secondly, we observed heterogeneity within the hRTDC population; both CD1c 1 and CD1c À DC subsets displayed evidence of phenotypic modulation in asthma that was independent of changes in population size. Other investigators have previously identified potent stimulatory subsets of CD1a 1 , CD1c 1 and BDCA-3 1 DC in human lung tissue, as well as a trace population of plasmacytoid DC that displayed only low levels of HLA-DR and co-stimulatory molecules [24] . The data presented in the current study are consistent with these findings, but extend the analysis of hRTDC populations to include quantitative determination of their phenotypic and endocytic modulation in asthmatic disease. It is unlikely that the DC populations we identified in sputum are a contaminating population derived from the blood since they lack the major subset of CD11c À DC (BDCA-2
that comprise approximately half of circulating blood DC [25] . Although the anatomical origin of DC obtained by sputum induction remains to be definitively identified, it is likely that many of these cells are derived from the tissues of the conducting airways as analysis using radiolabelled bolus delivery suggests that this is the major site sampled by the induced sputum technique [26] . The similarities between the data presented here and those reported by Demedts et al. [24] , in their study of biopsy-derived DC, and more specifically the presence of CD1a 1 DC in our samples (cells that are present in the epithelium of the conducting airways but not the lung parenchyma), strongly support the concept that the mucosa of the conducting airways contributes DC to the populations we have analysed. The relative contributions of lumenal, epithelial and submucosal DC populations are harder to determine and may be influenced by the ability of hypertonic saline to increase sampling of the deeper tissues.
While up-regulation of co-stimulatory molecules could simply be indicative of inflammatory activity, this does not provide an adequate explanation for changes in CD1c, CD1d and langerin expression by CD11c 1 hRTDC. Indeed, langerin can mediate the uptake of exogenous lipid antigen for CD1 presentation by DC [27] , and the activation of 'unconventional' T cells by this route could play a critical role in asthma pathogenesis [8] .
gd T cells and CD4 À CD8 À ab T cells can be activated by respiratory antigen presented in the context of CD1 [28] , and CD1d-restricted NKT cells could play a critical role in asthmatic disease [10] , but it is unclear whether DC presentation of CD1-restricted antigens is modulated in the asthmatic respiratory tract. CD1 molecules mediate the presentation of ubiquitous environmental antigens of both microbial and self origin [29, 30] . Cross-talk between DC and CD1-restricted T cells is bi-directional and can induce maturation of CD1 1 immature, myeloid DC that present appropriate self-antigen [6, 31] . There is also evidence that RTDC maturation can be induced by interaction with T cell subsets in the airway mucosa [32] . It is possible then that enhanced recognition of CD1 : selfantigen complexes in the pulmonary tissues leads to inappropriate hRTDC maturation by innate lymphocytes such as NKT cells [10] . Increased expression of co-stimulatory molecules could subsequently enhance hRTDC presentation of MHC/CD1-antigen complexes. Similar events have already been described in vitro; maturation of CD1c 1 myeloid DC -an abundant population in asthmatic sputum -can be induced by cell : cell contact with CD1c-restricted gd T cells [6] . The resultant mature, CD1c
1 DC are endocytic, can present novel protein antigen and are potent stimulators of naïve T cells, features identified as characterizing asthmatic, myeloid hRTDC in the current study. Vd1 1 gd T cells constitute the main tissue subset of gd T cells and recognize CD1c in the absence of foreign antigen [6] . These cells are predominantly auto-reactive and may facilitate rapid immune activation in the peripheral tissues. Vd1 1 gd T cells are enriched in the lungs of asthma patients following disease exacerbations and produce TNF-a upon mitogen stimulation [33] . gd T cells play an important role in pulmonary homeostasis [34] , and can produce TNF-a to induce maturation of CD1c 1 myeloid DC [6, 35] . TNF-a has been implicated in numerous models of DC maturation by innate lymphocytes [36] , and may depend upon up-regulated ICAM-1 expression and enhanced lymphocyte clustering [35] . It is intriguing therefore that TNF-a production is increased in the asthmatic lung [37] , and that allergen exposure induces ICAM-1 up-regulation and in situ maturation of pulmonary DC in a murine model of asthma [32, 38] .
Pollen contains bioactive lipids that can modulate DC function [39] . Pollen-derived lipids can also be presented by CD1
1 DC in vitro [9] , and are attractive candidates for CD1 presentation by hRTDC in the airways. In the current study, allergen inhalation enhanced CD1c expression by asthmatic myeloid hRTDC between 3-and 19-fold vs. the allergen-naïve phenotype. It is possible then that regulation of CD1 expression by hRTDC plays a critical role in allergic asthma, influencing DC maturation by innate lymphocytes and presentation of pollen-lipid antigens. Moreover, it is tempting to speculate that the ability of mycobacteria to inhibit CD1 expression by DC [40] may underpin the protection against asthma conferred by childhood exposure to mycobacterial products [41] .
Airway DC have been extensively studied in animal systems, but parallel work in the human system has lagged behind. The heterogeneity of hRTDC, when coupled with the diversity of methods, cell sources and animal models used to study these cells, probably accounts for the discrepancies observed in earlier data. The novel approach used by the current study limits the effects of ex vivo manipulation on RTDC phenotype [15, 16] , and avoids contamination with blood and peripheral lung DCpopulations that are distinct from mucosal hRTDC [32, 42] .
Currently, we can only speculate upon the possible reasons for the differential phenotype and function exhibited by myeloid hRTDC in asthma, but the data reported here are striking and may prove critical in asthma pathogenesis. Further definition of aberrant hRTDC function in allergic asthma will further our understanding of immune regulation in the human airway and may lead to the identification of novel targets for therapeutic interventions.
